CRD-740 is under clinical development by Cardurion Pharmaceuticals and currently in Phase II for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase II drugs for Diastolic Heart Failure (HFpEF) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CRD-740 LoA Report.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CRD-740 overview
CRD-740 is under development for the treatment of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). It is administered through oral route as tablet formulation. It acts by targeting PDE9.
Cardurion Pharmaceuticals overview
Cardurion Pharmaceuticals is a biopharmaceutical company that develops drugs to address the unmet needs of people suffering from heart diseases. Its drug pipeline portfolio includes phosphodiesterase-9 (PDE9) inhibition and calcium鈥揷almodulin-dependent protein kinase II (CaMKII) inhibition. Cardurion is developing drugs to treat cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmias, heart failure and other cardiac disorders. Cardurion Pharmaceuticals is headquartered in Burlington, Massachusetts, the US.
For a complete picture of CRD-740’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
